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The plant toxin, ricin (1,  2),  is composed of an  A  chain that enzymatically 
inactivates 60s ribosomes and a B chain that is a galactose-specific lectin (1). The 
A  chain  can  be  coupled  to  a  cell-reactive  antibody creating a  toxic  hybrid 
(immunotoxin). Many ricin A  chain-containing immunotoxins (IT) are not as 
toxic as IT containing intact ricin (3-8), possibly due to the capacity of B chain 
to facilitate the translocation of the A chain into the cytoplasm. We have recently 
shown that a B chain-containing IT (B-IT) can markedly potentiate the specific 
toxicity of an A chain-containing IT (A-IT) when both IT are directed against 
the same molecule on the target cells (9). An important variation of this approach 
with potential advantages for in vivo application would be to attach a univalent 
fragment of the cell-binding antibody to the A chain and an anti-antibody to the 
B chain. The univalent A-IT should remain on the target cell for an extended 
period of time and the secondary B-IT could be administered several hours later. 
Only cells coated with the A-IT that bind the B-IT should be killed. The present 
studies represent in vitro experiments to test the feasibility of this approach. 
Materials and Methods 
Cells.  Daudi cells were maintained and used as described previously (10, 11). 
Antibodies.  Affinity-purified  rabbit  anti-human  Ig  (RAHIg),  goat  anti-rabbit  Ig 
(GARIg), goat anti-ovalbumin (GA-OVA), and rabbit anti-ricin (RAR) were prepared as 
described (9-11). 
Ricin  A  and B  Chains.  The A and B chain subunits of ricin were purchased  from 
Worthington Biochemical Corp. and evaluated for purity and activity as described previ- 
ously (9-12). 
Preparation ofF(ab')Fragments of RAHIg.  F(ab')2  fragments of  affinity-purified RAHIg 
antibodies were prepared by pepsin digestion (13). Undigested antibody was removed on 
protein A-Sepharose. F(ab')2 fragments were affinity-purified on Sepharose-human Ig (9). 
F(ab')  fragments were  prepared  from F(ab')~ fragments  by reduction with  10  mM 
dithiothreitol (DTT) and alkylation with 22 mM iodoacetamide. 
Preparation and Affinity  Purification  of IT.  IT containing intact Ig or alkylated F(ab)' 
fragments were prepared, separated  from free ricin chains and were affinity purified as 
described previously (9). The recovery of the IT after affinity purification averaged  20- 
40% (9). As assessed by radioimmunoassay (RIA), each IT contained  1-3 A or B chains 
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FIGURE  1.  GARIg-B  potentiates the  killing of Daudi  cells treated  with  RAHlg-A. (Top) 
Three treatment protocols were used: (a) Cells (1 ×  105/well) were treated for 15 rain at 4°C 
in BSS (0.1 ml/well) containing RAHIg-A (final concentration, 1.1  ×  10  -s M). Cells were 
washed and then treated for 15 rain. at 4°C with BSS ([3); (b) cells were treated for 15 min at 
4 °C with BSS, washed, and treated with BSS containing  different concentrations  of GARIg-B 
(1 #g/ml =  4 ×  10  -9 M immunotoxin) ([~); (c) cells were treated with BSS containing 1.1  × 
10  -s  M  RAHIg-A, washed,  and treated  for  15  min at  4°C  in BSS  containing different 
concentrations of GARIg-B (ll). Control cultures were treated with BSS in both steps. Cells 
were washed, cultured for an additional 22 h, and labeled for 6 h with [3H]leucine. Cells were 
harvested, counted, and the leucine incorporation was compared with that of the control cells. 
(Middle) Cells were  treated as described  in the top panel except  that the GARIg was not 
attached  to B chain. (Bottom) Cells were  treated as described  in the top panel except  that 
GARIg +  1%  free B chain was used  instead  of the GARIg-B.  This is one representative 
experiment of six. 
per  molecule of antibody and  was contaminated with <1%  (and  usually undetectable 
levels) of free A or B chains. Alternatively, F(ab')2 fragments were reduced, desahed on 
Sephadex G-25, and reacted with a  100-fold molar excess of 5,5'-dithiobis(2-nitrobenzoic 
acid) (Eilman's reagent). Contamination of F(ab') by F(ab')~ ranged from undetectable 
levels to ~0.1%. The F(ab')-Ellman's was reacted with A chain and the F(ab')-A IT was 
purified as described previously (9).  F(ab')-A chain contained one A chain per molecule 
of F(ab'). 
Evaluation of IT.  IT were assessed for the presence of active antibody and either A or 
B chain by a  solid phase  RIA (3,  9) and by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) on 7% slab gels stained with silver (14). 
Treatment of Daudi Cells.  105 Daudi cells in balanced salt solution (BSS) were distrib- 
uted into wells (105/well) of a 96-well microtiter plate. Nontoxic dilutions of the RAHIg- 
A were added to triplicate wells for  15 min at 4°C. Cells were centrifuged and washed 
three times in BSS. Cells were then treated with the GARIg-B for 15 min at 4°C, washed 
three times in BSS, and cultured in 200 #l of RPMI lacking leucine and containing 10% 
fetal calf serum (FCS) for 22 h at 37°C in a  5% CO~ incubator. Cells were labeled with 
[3H]leucine (New England Nuclear, Boston, MA) and harvested as described previously 
(9).  At least nine wells of untreated cells were included as controls for each treatment 
group. The percent reduction in [3H]leucine incorporation as compared with the controls 
was used as the assessment of killing. 
Results 
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FIGURE  2.  Both divalent and univalent fragments of RAHIg-A kill  Daudi cells. Cells (1  x 
105/well) were treated for 15 rain at 4 o  C in BSS (0.1 ml/well) with the indicated concentrations 
of either divalent (RAHIg) (1/*g/ml -- 4.2 x  10  -9 M) or univalent [F(ab')] RAHIg-A (1 #g/ml 
=  7.2  ×  10  -9 M).  The  cells were  cultured  and  labeled as described in  Fig.  1.  This  is one 
representative experiment of three. 
neither 1.1  x  10 -s M RAHIg-A or GARIg-B at 8 X 10 -s to 2 ×  10 -9 M inhibited 
protein synthesis. However, when the cells were treated with RAHIg-A, washed, 
and then treated with different concentrations of GARIg-B, there was significant 
potentiation  of cytotoxicity. When  GARIg alone was  used  (Fig.  1 middle)  or 
when  GARIg  were  mixed  with  1%  free  B  chains  (the  maximum  estimated 
contamination of the secondary IT) (Fig.  1 bottom), no potentiation of the killing 
by RAHIg-A was observed. These experiments demonstrate that the potentiation 
of killing  is  dependent  upon  the covalent attachment of the  B  chain  to  the 
secondary antibody. 
An irrelevant secondary IT (GA-OVA-B) was ineffective at potentiating killing 
by the RAHIg-A (data not shown). In addition, an irrelevant primary IT (RA- 
OVA-A) or antibody (RAHIg) followed by the GARIg-B did not inhibit protein 
synthesis (data not shown). 
Ability of A Chain-Containing F(ab') Fragments of RAHIg to Kill Daudi Cells.  As 
seen in Fig.  2,  F(ab') fragments of RAHIg-A were highly toxic to Daudi cells, 
confirming earlier reports (15,  16). The titration curves using F(ab')-RAHIg-A 
chains and intact RAHIg-A were virtually identical. This was unexpected since 
the F(ab') fragments, in contrast to intact antibody, should not effectively cross- 
link cell surface Ig (sIg). The possibility was considered that the high content of 
A  chain  in  this  preparation  [F(ab')/A  ratio,  3:1]  caused  cross-linking of the 
surface Ig and rapid endocytosis of the Ig-IT complex. However, F(ab')-A-IT 
prepared  using  Ellman'  reagent  [F(ab')/A,  1:1]  killed  the  Daudi  cells  in  a 
comparable manner (data not shown) and immunofluorescence studies did not 
show any patching of sIg on  F(ab')-RAHIg-A-treated cells (data not shown). 
The effectiveness of F(ab')-A, compared with intact RAHIg-A-IT, may indicate 
that  these  different  ligands  enter  different endocytic vesicles  with  different 
potentials for A chain translocation. 
Ability of GARIg-B to Potentiate the Killing by F~ab') Fragments of RAHIg-A.  As 
shown in Fig. 3, top, nontoxic concentrations of the F(ab')-RAHIg-A caused only 
a  slight reduction in protein synthesis, and none of the concentrations of the 
GARIg-B were inhibitory.  However, when cells were treated with a  nontoxic 
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FIGURE 3.  GARIg-B potentiates the killing of Daudi cells treated with F(ab')-RAHIg-A. See 
Fig. 1 for experimental details. In this experiment, the F(ab')-RAHIg-A (final concentration, 
7.2  x  10 -9 M) was used in place of the intact  RAHIg-A (Fig.  I). This is one representative 
experiment of four. 
FIGURE 4.  The effect of delaying the time of addition of GARIg-B on the potentiation of 
the  killing of Daudi ,cells  by  F(ab')  RAHIg-A.  Daudi  cells were  treated  with  a  nontoxic 
concentration of F(ab )-RAHIgoA (7.2 ×  10-SM) as described in Fig. 1. The washed cells were 
incubated at 37 °C in complete medium for the indicated time intervals before being washed 
and treated with GARIg-B (final concentration, 2.5  x  10 -s M), as described in Fig.  1. Cells 
were washed,  cultured,  and  harvested as described in  Fig.  1.  Results are presented as the 
percentage of potentiation  obtained when  GARIg-B addition was not delayed. This is one 
representative experiment of three. 
of GARIg-B, there was significant potentiation of cytotoxicity. This potentiation 
was not observed with GARIg (Fig. 3, middle) or GARIg mixed with 1% B chains 
(Fig. 3, bottom). 
Effect of the Time Interval Between the Addition of the Primary and Secondary IT 
on In Vitro Killing of the Daudi Cells.  An important objective was to demonstrate 
that  F(ab')  fragments  of RAHIg-A  could  remain  on  the  cell  surface  so  that 
GARIg-B could  kill  such  cells when  administered  after an  interval  of several 
hours. Therefore, cells were treated for 15 min at 4 o  C with nontoxic concentra- 
tions of F(ab')-RAHIg-A, washed, and cultured at 37°C for various time inter- 
vals. Cells were then washed and treated for  15 min at 4°C with the GARIg-B, 
washed, and cultured at 37°C for 22 h.  As seen in Fig. 4, the effectiveness of 
potentiation  with increasing  time intervals between treatments with the F(ab')- 
RAHIg-A and the GARIg-B decreased in a  linear fashion.  50% of the control 
potentiation was observed at an interval of 5 h but no potentiation was observed 
after an interval of 10 h. 
Discussion 
Three  approaches  have been used in  vitro to exploit the  function of the  B 
chain in potentiating killing by ricin A-IT: (a) the use of ricin-containing  IT in 
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antibody  (17);  (b)  the  addition  of free  B  chains  to  A-IT  (7,  18);  and  (c)  the 
addition  of B-IT to A-IT in  which both IT are directed against  the same cell 
surface molecule (9).  Such  B-IT have  greatly reduced  lectin-binding  affinities 
(9). 
The present results have established the feasibility of using B-IT reactive with 
the univalent antibody of the A-IT to potentiate its specific toxicity. Furthermore, 
significant potentiation can be achieved after an interval of ~5 h. 
Full toxicity is achieved by the union of two different molecular species, only 
one of which,  F(ab')-A chain,  should be toxic to the reticuloendothelial  system 
(RES).  Furthermore,  FOb')  fragments  of  the  A-IT  should  not  bind  to  Fc 
receptors on nontarget  tissue. Hence, it should be possible to mark target cells 
in vivo with this IT.  Since F(ab') fragments are not reabsorbed by the kidney, 
the serum half-life is extremely short and 5 h later much of the excess F(ab')-A 
chain should have been excreted (19). At this time, B-IT directed to determinants 
on the F(ab') fragments could be administered.  B-IT have little or no inherent 
toxicity. However, their uptake by target cells coated with the F(ab')-A chain IT 
should result in potentiation of specific toxicity. 
There  are several potential  obstacles which must be overcome before using 
this strategy in vivo. (a) It may be necessary to develop B-IT that have an even 
lower binding affinity for galactose. This might be accomplished by altering the 
lectin-binding site on the B chain.  (b) IT are taken up by the mannose receptors 
on macrophages and cells of the RES (20) because of the mannose-rich oligosac- 
charide of the  ricin  chains  (2).  This  potential  problem could be overcome by 
removal of the carbohydrate moieties from the A and B chains. (c) It is unclear 
whether intact  B-IT can gain access to cells in lymphoid organs rapidly enough 
to bind to A-IT before they are removed from the cell surface. Hence, further 
information concerning the in vivo distribution, kinetics of clearance, and toxicity 
of these  IT is needed to properly design  effective therapeutic  regimens for in 
vivo use. 
Summary 
In  vitro  killing  of the  human  Daudi cell  line  by either  univalent  [F(ab')] or 
divalent (IgG) forms of rabbit anti-human  Ig (RAHIg) coupled to ricin A chain 
can  be specifically potentiated  by a  "piggyback"  treatment  with  ricin  B  chain 
coupled to goat anti-rabbit  Ig (GARIg).  When cells are treated with  univalent 
immunotoxin (IT) [F(ab') RAHIg-A] and then cultured,  IT can be detected on 
the cell surface for at least 5  h, since GARIg-B can still  enhance killing at this 
time. These results provide a  strategy for in vivo use of A chain- and B chain- 
containing IT. 
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